DURECT Corporation (DRRX)

NASDAQ: DRRX · IEX Real-Time Price · USD
0.751 -0.010 (-1.34%)
Jan 14, 2022 4:00 PM EST - Market closed
Market Cap170.79M
Revenue (ttm)5.49M
Net Income (ttm)-24.90M
Shares Out227.51M
EPS (ttm)-0.11
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,097,683
Open0.770
Previous Close0.761
Day's Range0.722 - 0.773
52-Week Range0.720 - 2.950
Beta1.15
AnalystsStrong Buy
Price Target6.00 (+699.3%)
Earnings DateNov 2, 2021

About DRRX

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients ...

IndustryPharmaceuticals
IPO DateSep 28, 2000
CEOJames Brown
Employees79
Stock ExchangeNASDAQ
Ticker SymbolDRRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for DURECT stock is "Strong Buy." The 12-month stock price forecast is 6.00, which is an increase of 699.25% from the latest price.

Price Target
$6.00
(699.25% upside)
Analyst Consensus: Strong Buy

News

Here's Why Durect (DRRX) is Poised for a Turnaround After Losing 17.1% in 4 Weeks

Durect (DRRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates coul...

3 days ago - Zacks Investment Research

DURECT Corporation to Participate in H.C. Wainwright Bioconnect Conference

CUPERTINO, Calif., Jan. 6, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E.

1 week ago - PRNewsWire

DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)

CUPERTINO, Calif. and ATHLONE, Ireland, Dec. 22, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced a licensing agreement granting Innocoll Biotherapeutics plc, a specialty pharmaceu...

3 weeks ago - PRNewsWire

DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter Ga...

CUPERTINO, Calif., Dec. 14, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the expansion of its board of directors with the appointment of Peter García, a biopharmaceutical indus...

1 month ago - PRNewsWire

DURECT Corporation to Participate in Alcoholic Liver Disease Workshop Today at the 5th Annual NASH Summit

CUPERTINO, Calif., Nov. 29, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced it will participate in a workshop today at the 5th Annual NASH Summit being held virtually from today through...

1 month ago - PRNewsWire

Data Presentation Today at The Liver Meeting® 2021 Shows Increasing Hospital Admissions for Alcohol-Associated Hepati...

CUPERTINO, Calif., Nov. 12, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the presentation of data at the American Association for The Study of Liver Diseases (AASLD) The Liver ...

2 months ago - PRNewsWire

DURECT Corporation Doses First ex-U.S. Patient in Phase 2b AHFIRM Study of Larsucosterol (DUR-928) in Severe Alcohol-...

CUPERTINO, Calif., Nov. 10, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it dosed the first ex-U.S. patient in Australia as part of its AHFIRM randomized, double-blind, placebo...

2 months ago - PRNewsWire

DURECT Corporation Announces Poster Presentation on the Prevalence of Hospitalized Alcohol-Associated Hepatitis (AH) ...

CUPERTINO, Calif., Nov. 8, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Suthat Liangpunsakul, M.D.

2 months ago - PRNewsWire

Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates

Durect (DRRX) delivered earnings and revenue surprises of 0.00% and -0.46%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

DURECT Corporation Reports Third Quarter 2021 Financial Results and Update of Programs

CUPERTINO, Calif., Nov. 2, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2021 and provided a corporate update.

2 months ago - PRNewsWire

DURECT Corporation to Announce Third Quarter 2021 Financial Results and Provide Business Update on November 2

CUPERTINO, Calif., Oct. 26, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its third quarter 2021 financial results and host a conference call after the marke...

2 months ago - PRNewsWire

Will Durect (DRRX) Report Negative Q3 Earnings? What You Should Know

Durect (DRRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

DURECT Corporation Fireside Chat at the H.C. Wainwright 5th Annual NASH Investor Conference

CUPERTINO, Calif., Oct. 7, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E.

3 months ago - PRNewsWire

DURECT Corporation Fireside Chat at the Cantor Fitzgerald Global Healthcare Conference 2021

CUPERTINO, Calif., Sept. 23, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E.

3 months ago - PRNewsWire

DURECT Corporation Fireside Chat at Oppenheimer's Fall Healthcare Life Sciences & MedTech Summit

CUPERTINO, Calif., Sept. 15, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E.

4 months ago - PRNewsWire

DURECT Corporation Fireside Chat at the H.C. Wainwright Annual Global Investment Conference

CUPERTINO, Calif., Sept. 7, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E.

4 months ago - PRNewsWire

Durect (DRRX) Reports Q2 Loss, Misses Revenue Estimates

Durect (DRRX) delivered earnings and revenue surprises of 0.00% and -16.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

DURECT Corporation Announces Second Quarter 2021 Financial Results and Update of Programs

CUPERTINO, Calif., July 29, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2021 and provided a corporate update.

5 months ago - PRNewsWire

DURECT Corporation to Announce Second Quarter 2021 Financial Results and Provide Business Update on July 29

CUPERTINO, Calif., July 22, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its second quarter 2021 financial results and host a conference call after the mark...

5 months ago - PRNewsWire

DURECT Corporation to Present at the 2021 Epigenetic Therapeutic Targets Virtual Summit

CUPERTINO, Calif., July 14, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it will present at the Epigenetic Therapeutic Targets Summit, being held virtually July 13-15, 2021.

6 months ago - PRNewsWire

DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic...

CUPERTINO, Calif., June 23, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the presentation of additional clinical data from a DUR-928 Phase 1b trial in non-alcoholic steatohepat...

6 months ago - PRNewsWire

Best Penny Stocks To Buy Now? 7 To Watch This Week

What are the best penny stocks to buy this week? The post Best Penny Stocks To Buy Now?

Other symbols:AEZSAMRNGLBSLOTZMDWD
6 months ago - PennyStocks

DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairm...

CUPERTINO, Calif., June 9, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it will present two posters at the 2021 International Liver Conference (EASL)  to be held virtually June...

7 months ago - PRNewsWire

Durect (DRRX) Reports Q1 Loss, Lags Revenue Estimates

Durect (DRRX) delivered earnings and revenue surprises of 0.00% and -15.99%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Durect: Q1 Earnings Insights

Shares of Durect (NASDAQ:DRRX) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were unchanged 0.00% year over year to ($0.05), which missed ...

8 months ago - Benzinga